Full history for every metric is available with a Kvantra account
Avadel Pharmaceuticals plc (AVDL)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 59 | 22 | 0 | 0 | 28 | 169 | 249 |
| Operating profit | $m | -42 | - | |||||
| Net profit | $m | -33 | 7 | -77 | -137 | -160 | -49 | - |
| EPS reported | $ | -0.51 | - | |||||
| Operating cashflow per share | $ | -0.49 | 0.37 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.49 | 0.37 | |||||
| Free cash flow | $m | -47 | 35 | |||||
| Net debt | $m | -74 | -54 | |||||
| Book value equity | $m | 74 | 98 | |||||
| Book value per share | $ | 0.78 | 0.97 | |||||
| Number of shares | m | 95.14 | 101.28 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 13.53 | 21.62 | |||||
| P/S LTM | x | 5.91 | 8.55 | |||||
| P/FCF LTM | x | -21.30 | 59.99 | |||||
| EV/EBITDA LTM | x | -26.69 | 204.32 | |||||
| EV/Sales LTM | x | 5.61 | 8.33 | |||||
| Earnings Yield LTM | % | -4.89% | 0.46% | |||||
| FCF Yield | % | -4.70% | 1.67% | |||||
| Quality | ||||||||
| ROE | % | -66.13% | 10.25% | |||||
| ROIC | % | -36.37% | 7.86% | |||||
| Operating margin | % | -25.07% | 7.43% | |||||
| Gross margin | % | 90.97% | 97.69% | |||||
| FCF/Sales | % | -27.74% | 24.56% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +504.79% | +79.88% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -27.53 | 0.95 | |||||
| Net Debt/EBITDA | x | 1.40 | -3.14 | |||||
| EBIT/Net interest | x | -3.91 | 2.27 | |||||
| Net debt/market cap | % | -7.39% | -2.55% | |||||
| Net debt/Equity | x | -1.00 | -0.55 | |||||
| Gross debt/equity | x | 0.02 | 0.38 | |||||
Company overview
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Avadel Pharmaceuticals plc (AVDL)
Avadel Pharmaceuticals plc is a biopharmaceutical firm primarily conducting its operations within the United States. The company's flagship investigational drug, FT218, a specialized compound of sodium oxybate, is currently in Phase 3 clinical trials. This therapeutic candidate aims to alleviate severe daytime somnolence and sudden muscle weakness (cataplexy) in adult individuals afflicted with narcolepsy. Established in 2015, the entity was formerly recognized as Flamel Technologies SA before rebranding as Avadel Pharmaceuticals plc in January 2017. Its global headquarters are situated in Dublin, Ireland.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free